Post Type Archives: News

Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, today reports its audited results for the year ended 31 December 2025. Said Darwazah, Chief Executive Officer (CEO) of Hikma, said: “Strong momentum in our Branded and Hikma Rx businesses and growth in all our geographies enabledus to deliver Group revenue and profit growth in line with guidance, […]

The Flamma Group, a global, fully integrated, Contract Development and Manufacturing Organization (CDMO) of New Chemical Entities (NCEs) and late stage intermediates for Innovator Companies, announces that its Flamma USA site, located in Malvern, PA, has successfully passed its first US Food and Drug Administration (FDA) inspection. The pre-approval inspection (PAI) took place over the […]

Bora Pharmaceuticals Co., Ltd., a global leader in pharmaceutical manufacturing, and GSK have signed a strategic agreement to renew a five-year manufacturing partnership. Bora purchased the Mississauga facility from GSK in 2020. This renewed collaboration reinforces the long-standing relationship between the two companies and expands the partnership, allowing GSK access to multiple sites within the […]

PureTech Health, a hub-and-spoke biotherapeutics company, announced on February 19th, 2026, that both FDA and the European Commission granted Orphan Drug Designation to deupirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF). Deupirfenidone is currently being advanced by Celea Therapeutics, a wholly-owned subsidiary of PureTech founded to lead deupirfenidone’s late-stage development and potential commercialization, and […]

AstraZeneca announced FDA approval of Calquence (acalabrutinib) in combination with venetoclax as a treatment for adults with chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma on February 20th, 2026. According to a company press release, it is the first oral, fixed-duration regimen treatment for these indications. Approval was based on results from the AMPLIFY Phase […]

Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), announced that it has strengthened its Advanced Synthesis offering to increase phase-appropriate support for the discovery and development of antibody-drug conjugates (ADCs) and other bioconjugates. The strengthened offering includes the full integration of the ADC technology platform, which will now be offered by […]

Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and research, today announced that it has acquired the ophthalmology business of Newcells Biotech (Newcells), a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services. The acquisition of Newcells’ ophthalmology business […]

Axplora, a global CDMO Partner for complex small molecules and antibody-drug conjugates (ADCs), announced a multi-million-euro investment to expand lyophilization (freeze-drying) capabilities at its Le Mans, France Site strengthening its ability to deliver reliable, efficient and fast ADC manufacturing for biotech and pharmaceutical customers. Axplora also announced the appointment of François Houbart as Head of […]

CSL, a global biotechnology company, and Eli Lilly and Company announced an exclusive licensing agreement. The agreement grants Eli Lilly certain rights to develop and commercialize clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody, while CSL will receive a $100 million payment upfront. CSL is also eligible for additional undisclosed milestone payments and royalties on global net […]

Olon, a global CDMO and generics manufacturer, and Zymvol, a leader in computational enzyme discovery and enzyme-enabled product development, today announced a strategic collaboration designed to accelerate the adoption of biocatalysis as a practical, scalable manufacturing solution for the pharmaceutical industry. The collaboration brings together Zymvol’s physics-AI powered enzyme design with Olon’s industrial-scale biomanufacturing capabilities, […]